Impacts of Nanomedicines in Ocular Pharmacotherapy
Introduction: The integrity of the cells/tissues in anterior and/or posterior segments of the eye plays a crucial role in biofunctions of the vision. To maintain ocular homeostasis, selective restrictiveness of the ophthalmic membranes and barriers control must act on shuttling of biomolecules. Thus...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tabriz University of Medical Sciences
2011-06-01
|
Series: | BioImpacts |
Subjects: | |
Online Access: | http://dx.doi.org/10.5681/bi.2011.003 |
id |
doaj-8d1037ec816c412bb9c67bb18d72b22d |
---|---|
record_format |
Article |
spelling |
doaj-8d1037ec816c412bb9c67bb18d72b22d2020-11-25T00:10:21ZengTabriz University of Medical SciencesBioImpacts2228-56522228-56602011-06-0111722Impacts of Nanomedicines in Ocular PharmacotherapyJaleh BararAilar NakhlbandIntroduction: The integrity of the cells/tissues in anterior and/or posterior segments of the eye plays a crucial role in biofunctions of the vision. To maintain ocular homeostasis, selective restrictiveness of the ophthalmic membranes and barriers control must act on shuttling of biomolecules. Thus, not all attempts to apply de novo nanotechnology approaches for ocular pharmacotherapy have met with the same successes as those cited here in this review, and sometimes these novel technologies tools provoke a great deal of challenges and hurdles mainly because of functional presence of these barriers. Methods: Recent published articles related to application of ocular nanomedicines were reviewed and highlighted in this review article. Results: It seems the emergence of nanomedicines have arisen great hopes for ophthalmic pharmacotherapy, in which nanostructured medicines are expected to be able to cross the restrictive barriers of the eye. Although such fast inauguration of ocular nanomedicines will literally convey new challenges in the regulatory and translational processes, it will also grant a prolific platform from which many exciting, and yet unimagined, applications of biomedical nanotechnology will emerge for pharmacotherapy of the eye. Conclusion: This review provide recent advancements on ocular nanomedicines.http://dx.doi.org/10.5681/bi.2011.003Molecular MedicineNanotechnologyNanomedicineOcular Drug DeliveryOphthalmology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jaleh Barar Ailar Nakhlband |
spellingShingle |
Jaleh Barar Ailar Nakhlband Impacts of Nanomedicines in Ocular Pharmacotherapy BioImpacts Molecular Medicine Nanotechnology Nanomedicine Ocular Drug Delivery Ophthalmology |
author_facet |
Jaleh Barar Ailar Nakhlband |
author_sort |
Jaleh Barar |
title |
Impacts of Nanomedicines in Ocular Pharmacotherapy |
title_short |
Impacts of Nanomedicines in Ocular Pharmacotherapy |
title_full |
Impacts of Nanomedicines in Ocular Pharmacotherapy |
title_fullStr |
Impacts of Nanomedicines in Ocular Pharmacotherapy |
title_full_unstemmed |
Impacts of Nanomedicines in Ocular Pharmacotherapy |
title_sort |
impacts of nanomedicines in ocular pharmacotherapy |
publisher |
Tabriz University of Medical Sciences |
series |
BioImpacts |
issn |
2228-5652 2228-5660 |
publishDate |
2011-06-01 |
description |
Introduction: The integrity of the cells/tissues in anterior and/or posterior segments of the eye plays a crucial role in biofunctions of the vision. To maintain ocular homeostasis, selective restrictiveness of the ophthalmic membranes and barriers control must act on shuttling of biomolecules. Thus, not all attempts to apply de novo nanotechnology approaches for ocular pharmacotherapy have met with the same successes as those cited here in this review, and sometimes these novel technologies tools provoke a great deal of challenges and hurdles mainly because of functional presence of these barriers. Methods: Recent published articles related to application of ocular nanomedicines were reviewed and highlighted in this review article. Results: It seems the emergence of nanomedicines have arisen great hopes for ophthalmic pharmacotherapy, in which nanostructured medicines are expected to be able to cross the restrictive barriers of the eye. Although such fast inauguration of ocular nanomedicines will literally convey new challenges in the regulatory and translational processes, it will also grant a prolific platform from which many exciting, and yet unimagined, applications of biomedical nanotechnology will emerge for pharmacotherapy of the eye. Conclusion: This review provide recent advancements on ocular nanomedicines. |
topic |
Molecular Medicine Nanotechnology Nanomedicine Ocular Drug Delivery Ophthalmology |
url |
http://dx.doi.org/10.5681/bi.2011.003 |
work_keys_str_mv |
AT jalehbarar impactsofnanomedicinesinocularpharmacotherapy AT ailarnakhlband impactsofnanomedicinesinocularpharmacotherapy |
_version_ |
1725408013514178560 |